Healthcare AI startup Harrison.ai has raised A $ 129 million (US $ 97 million) in a Series B funding round and has partnered with publicly traded medical diagnostics provider Sonic Healthcare to develop new AI tools in pathology.
WHAT IT DOES
Harrison.ai was founded in 2018 and is best known for its flagship product, Annalize CXR, an AI-based clinical decision support tool that reads chest x-rays. The device records 124 findings and is based on over 520,000 chest X-ray examinations comprising more than 820,000 individual images. It developed and marketed the tool together with I-MED Radiology early last year. Pathology aside, it has developed AI technology in IVF using Virtus Health.
WHAT IT IS FOR
According to a press release, the latest funds will be used to expand the company’s team of AI data scientists and engineers while also entering new markets with global partners.
Meanwhile, it has partnered with Sonic Healthcare to “quickly” commercialize new AI pathology solutions as it aims to help bridge the gap in the global pathology skill shortage.
THE BIGGER TREND
Diagnostic Imaging Provider Sonic Imaging recently deployed Annalize CXR in its 100 radiology clinics. According to Harrison.ai, around 350 Australian radiologists have used the device to date.
ON THE RECORD
“Providing equitable, effective and accurate health care to more people is an important part of our mission at Harrison.ai, and with the pandemic behind us, that mission is more important than ever. With our model and methodology, now proven in several clinical areas, we are able to expand into new clinical areas with the support of our investors and partners and fulfill our mission, “said Dr. Aengus Tran, co-founder and CEO of Harrison.ai.